Source comparison
Research Summary: Selank vs Semax Decision Matrix
Research question: anxiety-state impairment of working memory, fear generalisation, attentional filtering → Selank 0.3mg/kg i.n., flumazenil and pCPA controls, CUS or acute stress model, 48-72h onset readouts, Y-maze and fear discrimination endpoints. Research
This comparison does not assign a generated winner or score.
- Research question: anxiety-state impairment of working memory, fear generalisation, attentional filtering → Selank 0.3mg/kg i.n., flumazenil and pCPA controls, CUS or acute stress model, 48-72h onset readouts, Y-maze and fear discrimination endpoints.
- Research question: hippocampal neuroplasticity, LTP mechanisms, spine density, BDNF-TrkB signalling, spatial reference memory consolidation → Semax 50µg/kg i.n., K252a and SHU9119 controls, naive or mild-stress model, 7-14 day treatment, MWM and Barnes Maze endpoints, ex vivo slice LTP electrophysiology.
- Research question: combined anxiety-neuroplasticity interaction, PTSD-relevant cognitive research applications, sex differences in stress-impaired cognition → combined Selank+Semax, pharmacological double-dissociation design, CUS 21-28d, sex-stratified groups, multiday cognitive battery with washout probe trials.
- Models: C57BL/6J or Sprague-Dawley rat; CUS 14-28d (specify stressor protocol); naive control groups essential; sex-stratified if HPA axis is a study variable; home cage adaptation ≥7d before CUS onset; counterbalanced testing order for multi-task batteries.
- 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Selank and Semax for research and laboratory use. View UK stock →
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.